David John Peace MD

Oncology•Chicago, IL

Hematologic Oncology

Professor, Medicine, University of Illinois College of Medicine

Join to View Full Profile

1740 W Taylor StChicago, IL 60612
Phone+1 866-600-2273
Fax+1 312-413-4131

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1983 - 1987
UPMC Medical EducationResidency, Internal Medicine, 1981 - 1983
University of Pittsburgh School of MedicineClass of 1980

Certifications & Licensure

IL State Medical License 1992 - 2026
PA State Medical License 1981 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Start of enrollment: 2009 Nov 01
Completed
Phase 3
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction Start of enrollment: 2009 Jan 21
Terminated
Phase 1, Phase 2
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
ACTIVE_NOT_RECRUITING
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas Start of enrollment: 2010 Feb 01
Terminated
Phase 2
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
ACTIVE_NOT_RECRUITING
PHASE2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
ACTIVE_NOT_RECRUITING
PHASE3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

3 citations
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohor...
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen
Journal for Immunotherapy of Cancer. 2024-04-11
6 citations
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043.
Yousef Zakharia, Eric A Singer, Satwik Acharyya, Rohan Garje, Monika Joshi
Nature Communications. 2024-02-01
Unexpected heterogeneity in oropharyngeal squamous cell tumors.
David J Peace, Evgeny Izumchenko, David Sidransky
Nature Genetics. 2023-04-01

Grant Support

Minority Based Community Clinical Oncology ProgramNational Cancer Institute2005–2011
A Pilot Phase IB Trial Of Psa-Peptide Based Specific Active ImmunotherapyNational Center For Research Resources2004
A Pilot Phase IB Trial Of A PSA Peptide VaccineNational Cancer Institute2000–2001
Specific T Cell Immunity To Mutated RAS ProteinNational Cancer Institute1992–1996
NCI Clinical Investigator AwardNational Cancer Institute1987–1991